Literature DB >> 3293760

Chemotherapy for metastatic Merkel cell carcinoma. Review of the M.D. Anderson Hospital's experience.

L G Feun1, N Savaraj, S S Legha, E G Silva, R S Benjamin, M A Burgess.   

Abstract

Thirteen patients with regional or distant metastases from Merkel cell carcinoma were treated with combination chemotherapy. Three patients had a complete response to therapy. In two patients with nodal disease the duration of response was 10+ and 4+ years. In addition, three patients had a partial response, and six patients had minor responses. Chemotherapy using a combination of drugs that are active against small cell carcinoma of the lung is recommended in the treatment of unresectable disease in patients with Merkel cell carcinoma; it may produce prolonged responses. While tumor regressions as a result of chemotherapy were often dramatic, once the disease progressed, the course of the disease often moved rapidly downhill and proved to be fatal.

Entities:  

Mesh:

Year:  1988        PMID: 3293760     DOI: 10.1002/1097-0142(19880815)62:4<683::aid-cncr2820620406>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Therapeutic options for treatment of Merkel cell carcinoma.

Authors:  Kathrin Gessner; Gunnar Wichmann; Andreas Boehm; Anett Reiche; Julia Bertolini; Johannes Brus; Ina Sterker; Stefan Dietzsch; Andreas Dietz
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-08-27       Impact factor: 2.503

2.  Primary neuroendocrine (merkel cell) carcinoma of the anterior skull base.

Authors:  C Matula; K Roessler; M Burian; H Schuster; S Trattnig; J A Hainfellner; H Budka
Journal:  Skull Base Surg       Date:  1997

Review 3.  Immunotherapy for Merkel Cell Carcinoma.

Authors:  Kotaro Nagase; Yutaka Narisawa
Journal:  Curr Treat Options Oncol       Date:  2018-09-20

4.  A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331).

Authors:  Wolfram E Samlowski; James Moon; Ralph J Tuthill; Michael C Heinrich; Naomi S Balzer-Haas; Stuart A Merl; Ronald C DeConti; John A Thompson; Merle T Witter; Lawrence E Flaherty; Vernon K Sondak
Journal:  Am J Clin Oncol       Date:  2010-10       Impact factor: 2.339

5.  Neurologic complications of Merkel cell carcinoma.

Authors:  S M Snodgrass; H Landy; A M Markoe; L Feun
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

6.  Surgical management of Merkel cell carcinoma.

Authors:  P J Allen; Z F Zhang; D G Coit
Journal:  Ann Surg       Date:  1999-01       Impact factor: 12.969

7.  G3139 (Genasense) in patients with advanced merkel cell carcinoma.

Authors:  Manisha H Shah; Kimberly A Varker; Minden Collamore; James A Zwiebel; Daniel Coit; David Kelsen; Ki Y Chung
Journal:  Am J Clin Oncol       Date:  2009-04       Impact factor: 2.339

Review 8.  Immunotherapy for Merkel cell carcinoma: a turning point in patient care.

Authors:  Isaac S Chan; Shailender Bhatia; Howard L Kaufman; Evan J Lipson
Journal:  J Immunother Cancer       Date:  2018-03-23       Impact factor: 13.751

Review 9.  Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma.

Authors:  Paul Nghiem; Howard L Kaufman; Murtuza Bharmal; Lisa Mahnke; Hemant Phatak; Jürgen C Becker
Journal:  Future Oncol       Date:  2017-03-28       Impact factor: 3.404

10.  Merkel cell carcinoma.

Authors:  Virve Koljonen
Journal:  World J Surg Oncol       Date:  2006-02-08       Impact factor: 2.754

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.